Vericel Corporation Gross Profit 2011-2025 | VCEL

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Vericel Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
172 M	136 M	110 M	106 M	84.2 M	80.3 M	58.7 M	33.6 M	26.1 M	24.7 M	11.5 M	15 K	15 K	14 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
172 M	14 K	60.2 M

Quarterly Gross Profit Vericel Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
49.6 M	46.6 M	36.3 M	-	41.7 M	36.6 M	35.4 M	-	30.6 M	29.9 M	26.5 M	-	25.2 M	22.9 M	23.5 M	-	22.1 M	26.9 M	23 M	33.6 M	22.5 M	11.4 M	16.8 M	28.8 M	21.2 M	17.1 M	13.2 M	22.7 M	14.3 M	11.3 M	10.4 M	15 M	7.07 M	9.28 M	2.25 M	15 M	4.07 M	5.52 M	7.55 M	8.19 M	4.54 M	6.69 M	5.28 M	7.95 M	4.13 M	-577 K	-	-	-	2 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
49.6 M	-577 K	18.6 M

Gross Profit of other stocks in the Biotechnology industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	374 M	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	180 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	-40.6 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	172 K	$ 3.26	-3.12 %	$ 252 M	USA
Acasti Pharma ACST	-32.3 K	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	1.12 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	-523 K	-	-11.43 %	$ 502 K	USA
Kamada Ltd. KMDA	70 M	$ 7.03	0.14 %	$ 260 M	Israel
Alexion Pharmaceuticals, Inc. ALXN	5.52 B	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	319 M	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	39.2 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	90 K	-	-	$ 7.46 M	Israel
Can-Fite BioPharma Ltd. CANF	2.03 M	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	177 K	$ 3.3	-3.51 %	$ 7.94 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	12.1	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	43.9 B	$ 89.78	-0.57 %	$ 96.9 B	Britain
Midatech Pharma plc MTP	-428 K	-	-18.52 %	$ 27.3 M	Britain
Anika Therapeutics ANIK	103 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	1.82 K	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	3.22 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	500	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	53.8 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	282 K	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	45.8 M	$ 2.34	2.59 %	$ 14.7 M	USA
Nymox Pharmaceutical Corporation NYMX	1 K	-	-19.68 %	$ 18.4 M	Canada
Arena Pharmaceuticals ARNA	319 K	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	-104 K	$ 1.29	-3.01 %	$ 7.03 M	China
Baudax Bio BXRX	-1.24 M	-	0.59 %	$ 63 K	USA
Институт стволовых клеток человека ISKJ	774 M	-	-	-	Russia
Catalyst Biosciences CBIO	109 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	61.6 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	1.24 B	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	60.4 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	1.07	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	4.15 M	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	123 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	12.4 B	$ 174.42	1.11 %	$ 25.4 B	USA
Celldex Therapeutics CLDX	5.48 M	$ 27.36	-2.09 %	$ 1.76 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	371 M	$ 11.54	0.87 %	$ 746 M	USA